NEW YORK (GenomeWeb) – A comparison of commercially available multigene breast cancer recurrence signatures suggests that some tests may be better than others at assessing which patients are at risk for late distant recurrence, which could be impacting oncologists' ability to guide appropriate treatment decisions for patients. 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.